Aug 13, 2025 | Legal Compliance, Marketing & Advertising Law, News
If you’ve been keeping an eye on the wellness world lately, you’ve probably noticed a new buzzword popping up everywhere: NAD+. From IV drips at high-end med spas to celebrity biohacking routines, it’s quickly become one of the most talked-about treatments for...
Jul 16, 2025 | Legal Compliance, News, State-Specific Regulations
Colorado’s House Bill 25-1024 (HB25-1024), signed into law on April 7, 2025, adds critical obligations for medical professionals who delegate medical-aesthetic procedures to unlicensed staff. If you’re a Colorado physician or advanced practice registered nurse...
Jul 15, 2025 | Legal Compliance, News
Semaglutide, the active ingredient in Ozempic and Wegovy, is set to lose patent protection in China on March 20, 2026. This is years ahead of its expiration in the United States, Europe and Japan. As that date approaches, Chinese pharmaceutical companies (as well as...
Jun 18, 2025 | Legal Compliance, News
Novo Nordisk, the pharmaceutical company behind Ozempic and Wegovy, is starting to lose its wave of lawsuits against compounders and related businesses offering semaglutide copycats. But here’s the reality that isn’t making headlines: even when Novo loses, the process...
Jun 18, 2025 | News, State-Specific Regulations
The North Carolina Board of Nursing and the North Carolina Medical Board have recently increased their investigative and enforcement efforts, appearing to target med spas and other wellness and aesthetics businesses. The majority of investigations we’re seeing are...
Jun 10, 2025 | News, State-Specific Regulations
As the popularity of GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound continues to grow, Nevada compounding pharmacies are now facing significant regulatory changes. The Nevada State Board of Pharmacy has issued a directive that prohibits the...
